Abstract 1117P
Background
Skin melanoma, particularly acral melanoma, is known for its poor prognosis, often exacerbated by infections and chronic ulcers. Recent research has highlighted the significant role of intratumoral microbiota in various cancers, but its impact remains less understood in Chinese patients with skin melanoma. This study aims to investigate the intratumoral microbiota in melanoma among this group and explore its potential influence on disease progression.
Methods
One hundred melanoma tissue samples from stage III/IV skin or acral melanoma patients at Sun Yat-sen University Cancer Center, collected between 2015 and 2021, were retrospectively collected and underwent LPS immunohistochemistry (IHC). Kaplan-Meier analysis was used to assess the relation of LPS expression and patients overall survival. Microbial diversity was analyzed through 16S rRNA sequencing. Spatial transcriptomics was applied to map LPS-positive and LPS-negative regions, enabling the exploration of transcriptional differences and cell distributions.
Results
Patients with high LPS levels exhibited a median overall survival (mOS) of 13.7 months (95% CI, 10.6–16.9), which was shorter compared to those with low LPS levels, who had not yet reached median survival. Analysis of tumor microbiota revealed significant diversity, with high proportions of Bifidobacterium, Vibrio, Bacillus, Clostridium sensu stricto, and Pseudomonas, among which Pseudomonas was the dominant genus. Spatial transcriptomic analysis of LPS-positive melanoma tissues showed an increased proportion of M2 macrophages and a decreased proportion of effector T cells. Gene set enrichment analysis (GSEA) further indicated the activation of epithelial-mesenchymal transition (EMT) pathways.
Conclusions
High levels of microbiota within melanoma tissues are correlated with poor overall survival and may facilitate tumor immune evasion and metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1122P - The role of imaging during follow-up after radical surgery of stage IIb-c and III cutaneous malignant melanoma: Survival results from an interim analysis of a randomized prospective multicenter study (TRIM)
Presenter: Cecilia Ladjevardi
Session: Poster session 04
1123P - Melanoma incidence and mortality decline in younger adults in Sweden: Start of a shift in the upgoing trend?
Presenter: Hildur Helgadottir
Session: Poster session 04
1124P - Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study
Presenter: Elisabeth Livingstone
Session: Poster session 04
1125P - Accuracy of PET-CT to assess extent of nodal disease in clinical stage III melanoma
Presenter: Ronen Stoff
Session: Poster session 04
1126P - A phase II study of nivolumab/relatlimab in metastatic uveal melanoma
Presenter: Jose Lutzky
Session: Poster session 04
1127P - Subgroup analysis of FOCUS phase III trial efficacy results
Presenter: Matthew Wheater
Session: Poster session 04
1128P - Preliminary results of first-in-human study of 225-Actinium MTI-201 (225Ac-MTI-201) in metastatic uveal melanoma
Presenter: Nikhil Khushalani
Session: Poster session 04
1129P - Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM)
Presenter: Paul Nathan
Session: Poster session 04
1130P - Phase II trial on nivolumab plus radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial
Presenter: Motoo Nomura
Session: Poster session 04
1131P - A phase II study of pembrolizumab combination with temozolomide as 1L treatment for Chinese metastatic acral melanoma patients
Presenter: Ya Ding
Session: Poster session 04